Julio C Aguilar, Sheikh Mf Akbar, Mamun Al-Mahtab, Md Sakirul I Khan, Carlos A Guzman, Guillermo Fernandez, Jorge A Aguiar, Marie-Louise Michel, Maryline Bourgine, Maria A Marrero, Stephanie Trittel, Thomas Ebensen, Peggy Riese, Roger Le Grand, Cecile Herate, Aurelie Mauras, Osamu Yoshida, Yoichi Hiasa, Eduardo Penton, Gerardo E Guillen
{"title":"HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.","authors":"Julio C Aguilar, Sheikh Mf Akbar, Mamun Al-Mahtab, Md Sakirul I Khan, Carlos A Guzman, Guillermo Fernandez, Jorge A Aguiar, Marie-Louise Michel, Maryline Bourgine, Maria A Marrero, Stephanie Trittel, Thomas Ebensen, Peggy Riese, Roger Le Grand, Cecile Herate, Aurelie Mauras, Osamu Yoshida, Yoichi Hiasa, Eduardo Penton, Gerardo E Guillen","doi":"10.5005/jp-journals-10018-1457","DOIUrl":null,"url":null,"abstract":"<p><p>The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.</p><p><strong>How to cite this article: </strong>Aguilar JC, Akbar SMF, Al-Mahtab M, <i>et al.</i> HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.</p>","PeriodicalId":516317,"journal":{"name":"Euroasian journal of hepato-gastroenterology","volume":"14 2","pages":"221-237"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714097/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euroasian journal of hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10018-1457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
How to cite this article: Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
免疫系统在控制急性乙型肝炎感染和解决慢性乙型肝炎（CHB）患者中起着核心作用。鉴于2.21亿（75%）慢性乙型肝炎患者居住在低收入和中等收入国家，开发具有治疗特性的疫苗是一种合理且具有成本效益的方法，而不是一种不切实际的努力。本综述系统地分析了与慢性乙型肝炎治疗的安全性、有效性和有效性相关的关键变量。为了解决治疗性疫苗的挑战和潜力，以及目前在研发、注册和大规模实施方面的障碍，我们重新审视了HeberNasvac的经验。如何引用本文：Aguilar JC， Akbar SMF, al - mahtab M，等。慢性乙型肝炎的研究进展与应用[J] .中华肝病与胃肠病学杂志；2014;14(2):221-237。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
